- Home
- ROIV vs STLA Comparison
ROIV vs STLA Comparison
Compare ROIV & STLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | STLA |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United Kingdom | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 19.4B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ROIV | STLA |
|---|---|---|
| Price | $28.02 | $7.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $28.94 | $11.59 |
| AVG Volume (30 Days) | 4.4M | ★ 17.8M |
| Earning Date | 05-28-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 7.50% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,053,000.00 | N/A |
| Revenue This Year | N/A | $7.18 |
| Revenue Next Year | $744.61 | $3.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.58 | $6.28 |
| 52 Week High | $30.33 | $12.22 |
Technical Indicators
Market Signals| Indicator | ROIV | STLA |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 36.31 |
| Support Level | $27.00 | $7.07 |
| Resistance Level | $30.26 | $10.31 |
| Average True Range (ATR) | 0.90 | 0.23 |
| MACD | -0.14 | -0.14 |
| Stochastic Oscillator | 31.41 | 8.57 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About STLA Stellantis N.V.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.